scholarly journals Effectiveness of local application of antiseptic with octenidin dihydrochloride molecule in smoking women with ASC-US and LSIL

2021 ◽  
pp. 90-96
Author(s):  
O.O. Akulina
Keyword(s):  
Human Papillomavirus ◽  
Pap Smear ◽  
Pap Test ◽  
Intraepithelial Neoplasia ◽  
Laboratory Assessment ◽  
Human Papillomavirus 16 ◽  
Second Stage ◽  
Octenidine Dihydrochloride ◽  
Therapy Effectiveness ◽  
Positive Effect

This article presents the results of our own experience of topical use of the Prodexin antiseptic that is contained an octenidine dihydrochloride molecule as a monotherapy for ASC-US and LSIL cervical pathology (identified with in fluid cytology) associated with human papillomavirus in smoking women.Study objective: To study the efficacy of topical application of the octenidine dihydrochloride molecule in the Prodexin vaginal suppositories in the treatment of smoking women with ASC-US and LSIL.Materials and methods. The study involved 45 female smokers with identified ASC-US or LSIL. The complex of examination included: Pap test based on liquid cytology, testing for human papillomavirus 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 types in a quantitative format, screening for the causes of vaginitis, extended colposcopy to exclude cervical intraepithelial neoplasia II+. Prodexin suppositories were used according to a 3-month treatment regimen (20 suppositories daily, and then 10 suppositories in two consecutive cycles).Results. Clinical and laboratory assessment of the therapy effectiveness has convincingly shown its positive effect on the vagina and cervix. Treatment with the Prodexin antiseptic associated with microbiota normalization, colposcopic picture improvement and changes in the Pap smear to NILM I or II. Regress to NILM was recorded in 20 (86.9%) patients with ASC-US and in 15 (68.8%) women with LSIL.Conclusions. Prodexin allows to avoid a worsening of the situation and prevent the changes progression in HSIL. Proposed treatment had no side effects, was convenient to use and did not require additional visits to doctor during therapy. The control over the human papillomavirus and study of the viral load has been postponed for 6–12 months from the beginning of the examination, that will be the second stage of work.

Providing high quality information about human papillomavirus for women after treatment for high-grade cervical dysplasia

Sexual Health ◽  
2010 ◽  
Vol 7 (1) ◽  
pp. 49 ◽  
Author(s):  
Suzanne Dyson ◽  
Marian Pitts ◽  
Anthony Lyons ◽  
Robyn Mullins
Keyword(s):  
Human Papillomavirus ◽  
Information Needs ◽  
Qualitative Interviews ◽  
Cervical Dysplasia ◽  
Pap Test ◽  
Intraepithelial Neoplasia ◽  
General Information ◽  
High Grade ◽  
Hpv Testing

Background: The present study aimed to inform the production of a resource for women who have had a high-grade cervical abnormality and are scheduled to undergo testing for human papillomavirus (HPV) at their 12-month follow-up. Methods: Two rounds of semi-structured, qualitative interviews were held with women who were attending a gynaecological oncology clinic at a major teaching hospital for women in Melbourne, Australia, 6 months after treatment for cervical intraepithelial neoplasia (CIN) to receive a follow-up Pap test and colposcopy. In an initial round of interviews, we gauged the reactions of 16 women to an existing information brochure containing general information about HPV. Based on the findings from the interviews, a second brochure aimed specifically for women scheduled to undergo HPV testing as part of their post treatment follow-up was drafted. Feedback was then gathered from a further 12 women. Results: While all participants had received some information and counselling about HPV and HPV testing as part of their treatment, many still experienced high levels of stress and anxiety about cancer and the sexually transmissible nature of HPV. Many also still had unanswered questions about HPV, their treatment regime and future prognosis. Conclusion: For a brochure to provide an effective adjunct to counselling, it is essential that it is carefully developed and pilot tested to ensure that it is easily understood and meets the information needs of the target audience. Such materials need to provide both medical and psychosocial information about HPV and be presented in accessible, easy to understand language.

Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia

2006 ◽  
Vol 16 (3) ◽  
pp. 1032-1035
Author(s):  
S. N. Tabrizi ◽  
I. H. Frazer ◽  
S. M. Garland
Keyword(s):  
Human Papillomavirus ◽  
Cervical Intraepithelial Neoplasia ◽  
Intraepithelial Neoplasia ◽  
High Grade ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Human Papillomavirus 16 ◽  
Serologic Response ◽  
Poor Predictor ◽  
Hpv Types

This study evaluated the detection of human papillomavirus (HPV) 16 antibody in HPV 16–associated cervical intraepithelial neoplasia (CIN) in Australian women. Seroreactivity to HPV 16 L1 virus–like particles was assessed in patients with CIN 2 (n = 169) and CIN 3 (n = 229) lesions previously tested for the presence of HPV DNA. Seropositivity was significantly commoner in women with HPV 16 DNA–positive lesions (98/184) than in women with no HPV DNA in the lesion (15/47) or with HPV of types other than 16 in the lesion (43/167) (P = 0.0004). In addition, seropositivity was observed in 33% (55/169) of women with CIN 2 and 46% (106/229) of women with CIN 3, in keeping with the lower fraction of CIN 2 (57/169) than CIN 3 (127/229) biopsies positive for HPV 16 DNA. HPV 16 seropositivity is most common in women with HPV 16–associated CIN, but many patients with HPV-associated CIN 3 are seronegative, and HPV 16 seropositivity is common in women with CIN associated with other HPV types. Overall, HPV 16 serology is a poor predictor of presence of HPV 16–associated CIN 3 in patient population studied.

Performance of the Roche AMPLICOR® Human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear

2005 ◽  
Vol 99 (1) ◽  
pp. 160-168 ◽  
Author(s):  
Joseph Monsonego ◽  
Jean Marc Bohbot ◽  
Giuseppe Pollini ◽  
Claude Krawec ◽  
Catherine Vincent ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Intraepithelial Neoplasia ◽  
Pap Smear ◽  
Intraepithelial Neoplasia ◽  
Hpv Test

Immunotherapy of cervical intraepithelial neoplasia associated with human papillomavirus in the COVID-19 pandemic. Clinicians’ view

2021 ◽  
Vol 20 (5) ◽  
pp. 131-135
Author(s):  
A.I. Davydov ◽  
◽  
R.A. Chilova ◽  
M.N. Shakhlamova ◽  
V.A. Lebedev ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Intraepithelial Neoplasia ◽  
Intraepithelial Neoplasia ◽  
Postoperative Treatment ◽  
Review Of The Literature ◽  
Inosine Pranobex ◽  
Standard Regimen ◽  
Second Stage ◽  
Cervical Surgery ◽  
Inflammatory Syndrome

In the context of the COVID-19 pandemic, the connection between SARS-CoV-2 and other immune-dependent human conditions, including cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV), are being discussed. A review of the literature and the results of observation of patients who are currently receiving therapy with inosine pranobex (IP) according to the standard regimen (as the second stage after organ-preserving cervical surgery) indicate the absence of any abnormalities during the postoperative period. Moreover, publications on the interaction of IP and COVID-19 provide a chance for a favorable outcome regarding not only the treatment of CIN, but also minimizing the inflammatory syndrome in case of SARS-CoV-2 infection. Conclusion. The use of IP as medication-assisted (postoperative) treatment of patients with CIN-HPV in the COVID-19 pandemic conditions is, firstly, as effective with respect to cervical pathology as it is outside the pandemic; secondly, in case of SARS-CoV-2 infection, it can potentially reduce the severity of the course and consequences of respiratory viral infection. Key words: COVID-19, SARS-CoV-2, cervical intraepithelial neoplasia, inosine pranobex

Sign in / Sign up

Export Citation Format

Share Document